Fidocure®

Fidocure® company information, Employees & Contact Information

Explore related pages

Related company profiles:

FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports. FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button. FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions. Learn more at www.fidocure.com.

Company Details

Employees
23
Founded
-
Address
228 Hamilton Ave, Palo Alto,california 94301,united States
Industry
Biotechnology
HQ
Palo Alto, California
Looking for a particular Fidocure® employee's phone or email?

Fidocure® Questions

News

FidoCure Study Unlocks Breakthroughs in Deadliest Dog Cancer - Business Wire

FidoCure Study Unlocks Breakthroughs in Deadliest Dog Cancer Business Wire

FidoCure Unleashes Fetch™: AI Engine Analyzes Real-World Evidence To Optimize Cancer Therapies for Dogs - Business Wire

FidoCure Unleashes Fetch™: AI Engine Analyzes Real-World Evidence To Optimize Cancer Therapies for Dogs Business Wire

Novel, targeted canine cancer therapy receives US patent - DVM360

Novel, targeted canine cancer therapy receives US patent DVM360

Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcoma - Nature

Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcoma Nature

FidoCure CEO Thinks Drugs For Dogs Can Help Humans Fight Cancer - Forbes

FidoCure CEO Thinks Drugs For Dogs Can Help Humans Fight Cancer Forbes

Fidocure — A New Approach to Canine Cancers - Kinship

Fidocure — A New Approach to Canine Cancers Kinship

One Health Company partners with IDEXX to enhance canine cancer care - DVM360

One Health Company partners with IDEXX to enhance canine cancer care DVM360

FidoCure To Unveil Breakthrough in Canine Hemangiosarcoma at 2024 Veterinary Cancer Society Annual Conference - Business Wire

FidoCure To Unveil Breakthrough in Canine Hemangiosarcoma at 2024 Veterinary Cancer Society Annual Conference Business Wire

FidoCure Receives Patent for AI-Driven Drug Development, Accelerating a Novel Portfolio of Precision Therapeutic for Cancer - Business Wire

FidoCure Receives Patent for AI-Driven Drug Development, Accelerating a Novel Portfolio of Precision Therapeutic for Cancer Business Wire

Top Fidocure® Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant